3 ms·
>> You're making sure that there are antibodies in there and that they would be effective? > Exactly. Exactly—that we have a potent unit. We think that one pe
by koolba 7y ago
>> You're making sure that there are antibodies in there and that they would be effective?
> Exactly. Exactly—that we have a potent unit. We think that one person can treat two people.
Does this work in an ongoing chain? For example if person A’s plasma is used to treat B, can we take from B and treat C as well?
Or does the quality of the anti-bodies depend purely on the immune system of the hose?
- zaroth 7y agoOnce someone has been exposed and recovered, they should have the antibody concentration required to be become a donor themselves. The required number of cells we’re taking about is high enough that you’re not transfusing A->B and then recovering A from B’s plasma and going on to give A->C. But while B is infected they will make their own antibodies and after they recover they could then be a donor as in B->C. As TFA mentions, China doesn’t even bother testing the level of antibodies, they just collect the plasma from anyone recovered. 90 tons to Italy... is a lot of plasma. At least for IVIG the plasma is pooled from a large number of donors for each transfusion ultimately given to a patient. So it’s more a question of the average antibody load than needing to gauge each individual donor’s levels. > Each IVIG preparation is made from the pooled plasma of 3,000-10,000 blood donors, which is then purified to contain more than 90% antibodies. [1] I think we need to start collecting plasma from recovered positive cases today. I get that for a trial you do want to have a measured baseline of antibodies. But we can start stockpiling and pooling COVID antibody plasma even without the antibody testing. [1] - https://www.rheumaderm-society.org/ivig/ https://www.rheumaderm-society.org/ivig/